Heron Therapeutics Past Earnings Performance
Past criteria checks 0/6
Heron Therapeutics has been growing earnings at an average annual rate of 5.4%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 0.2% per year.
Key information
5.4%
Earnings growth rate
14.1%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -0.2% |
| Return on equity | n/a |
| Net Margin | -87.0% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Heron Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 127 | -111 | 103 | 0 |
| 30 Sep 23 | 123 | -120 | 105 | 0 |
| 30 Jun 23 | 118 | -137 | 112 | 0 |
| 31 Mar 23 | 114 | -151 | 118 | 0 |
| 31 Dec 22 | 108 | -182 | 119 | 0 |
| 30 Sep 22 | 98 | -217 | 127 | 0 |
| 30 Jun 22 | 95 | -227 | 134 | 0 |
| 31 Mar 22 | 90 | -232 | 135 | 0 |
| 31 Dec 21 | 86 | -221 | 127 | 0 |
| 30 Sep 21 | 86 | -228 | 117 | 0 |
| 30 Jun 21 | 83 | -234 | 104 | 0 |
| 31 Mar 21 | 83 | -228 | 96 | 0 |
| 31 Dec 20 | 89 | -227 | 102 | 0 |
| 30 Sep 20 | 103 | -223 | 100 | 0 |
| 30 Jun 20 | 126 | -198 | 103 | 0 |
| 31 Mar 20 | 140 | -193 | 112 | 0 |
| 31 Dec 19 | 146 | -205 | 128 | 0 |
| 30 Sep 19 | 140 | -196 | 126 | 0 |
| 30 Jun 19 | 117 | -201 | 124 | 0 |
| 31 Mar 19 | 98 | -190 | 111 | 0 |
| 31 Dec 18 | 77 | -179 | 94 | 0 |
| 30 Sep 18 | 59 | -192 | 88 | 0 |
| 30 Jun 18 | 47 | -195 | 84 | 0 |
| 31 Mar 18 | 39 | -199 | 85 | 0 |
| 31 Dec 17 | 31 | -197 | 82 | 0 |
| 30 Sep 17 | 22 | -183 | 78 | 0 |
| 30 Jun 17 | 13 | -190 | 75 | 0 |
| 31 Mar 17 | 5 | -190 | 70 | 0 |
| 31 Dec 16 | 1 | -173 | 69 | 0 |
| 30 Sep 16 | 0 | -156 | 65 | 0 |
| 30 Jun 16 | 0 | -131 | 56 | 0 |
| 31 Mar 16 | 0 | -110 | 47 | 0 |
| 31 Dec 15 | 0 | -98 | 36 | 0 |
| 30 Sep 15 | 0 | -87 | 28 | 0 |
| 30 Jun 15 | 0 | -83 | 24 | 0 |
| 31 Mar 15 | 0 | -79 | 22 | 0 |
| 31 Dec 14 | 0 | -76 | 20 | 0 |
| 30 Sep 14 | 0 | -70 | 22 | 0 |
| 30 Jun 14 | 0 | -63 | 24 | 0 |
| 31 Mar 14 | 0 | -60 | 24 | 0 |
| 31 Dec 13 | 0 | -55 | 24 | 0 |
| 30 Sep 13 | 0 | -50 | 20 | 0 |
Quality Earnings: 0J4V is currently unprofitable.
Growing Profit Margin: 0J4V is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0J4V is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare 0J4V's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0J4V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 0J4V's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.